Omalizumab in the Treatment of Chronic Inducible Urticaria.
Sign Up to like & getrecommendations! Published in 2017 at "Actas dermo-sifiliograficas"
DOI: 10.1016/j.ad.2016.07.018
Abstract: Omalizumab is a recombinant humanized monoclonal antibody that inhibits immunoglobulin E. It has been approved for the treatment of severe asthma and chronic spontaneous urticaria refractory to other treatments. Its use in the management of… read more here.
Keywords: inducible urticaria; omalizumab treatment; treatment chronic; chronic inducible ... See more keywords